title: Treatment and outcomes of Ewing sarcoma in Turkish adults: a single centre experience.
abstract: BACKGROUND
  Ewing sarcoma is a small round cell tumor arising from soft tissue and bone that predominantly affects children and adolescents. The most unfavorable prognostic factor is the presence of distant metastasis at the time of diagnosis.
  
  
  METHODS
  The records of 26 Ewing sarcoma patients (14 male, 12 female) were re-evaluated retrospectively.
  
  
  RESULTS
  The median age was 26.5 (19-42) years. Eight patients (31%) showed a primary tumor in their extremities, 8 (31%) in the thorax, 4 (15%) at the vertebra, 4 (15%) in the head and neck, and 2 (8%) in the abdomen. Five patients (19%) had distant metastasis at diagnosis. The median progression-free survival was 72 months and 10 months in localized and metastatic disease, respectively (p=0.005). The overall survival rate was 19 months in metastatic disease, and the 5-year overall survival rate was 64% in localized disease (p=0.006). Patients who had localized disease in the extremities and were under age 30 had a favorable prognosis.
  
  
  CONCLUSIONS
  Although Ewing sarcoma is a tumor affecting children and adolescents, it may be seen in adults, where the prognosis is generally worse. Although it is a highly malignant tumor, it is possible to achieve improved survival with combined modality treatments.
authors: Department of Medical Oncology, Cumhuriyet University Medical Faculty, Sivas, Turkey E-mail : mmetinseker@yahoo.com.tr.
authors: Mehmet Metin
authors: MM
authors: Seker
authors: Tugba
authors: T
authors: Kos
authors: Nuriye
authors: N
authors: Ozdemir
authors: Ayse
authors: A
authors: Seker
authors: Sercan
authors: S
authors: Aksoy
authors: Dogan
authors: D
authors: Uncu
authors: Nurullah
authors: N
authors: Zengin
mesh_terms: D000005:Abdomen; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005121:Extremities; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012512:Sarcoma, Ewing / Q000556:secondary / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000473:pathology / Q000628:therapy*; D013125:Spinal Neoplasms / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D013909:Thorax; D014421:Turkey; D055815:Young Adult